The methodology of Genome-Wide Association Screening (GWAS) has been applied for more than a decade. Translation to clinical utility has been limited, especially in Alzheimer's Disease (AD). It has become standard practice in the analyses of more than two dozen AD GWAS studies to exclude the apolipoprotein E (APOE) region because of its extraordinary statistical support, unique thus far in complex human diseases. New genes associated with AD are proposed frequently based on SNPs associated with odds ratio (OR) , 1.2. Most of these SNPs are not located within the associated gene exons or introns but are located variable distances away. Often pathologic hypotheses for these genes are presented, with little or no experimental support. By eliminating the analyses of the APOE-TOMM40 linkage disequilibrium region, the relationship and data of several genes that are co-located in that LD region have been largely ignored. Early negative interpretations limited the interest of understanding the genetic data derived from GWAS, particularly regarding the TOMM40 gene. This commentary describes the history and problem(s) in interpretation of the genetic interrogation of the "APOE" region and provides insight into a metabolic mitochondrial basis for the etiology of AD using both APOE and TOMM40 genetics. 
In a seminar for medical students on the philosophy of science regarding research methodology, the question was raised regarding "how to keep-up with massive amount of literature." The answer was that, even for an investigator working in a highly specialized field, it is extremely difficult to be current. One approach to this dilemma is the strategy for reading research articles suggested by the late G. Milton Shy, Professor and Chairman of Neurology, University of Pennsylvania School of Medicine which was to "forget the abstract, which is basically the authors' interpretations but rather focus on the data and the published interpretation. Ask the question of whether the methods and analyses support the conclusions."
Even with modern "precision" genetic data, reader interpretations may miss the relevant facts. Specifically, as an illustrative example, this perspective will explain how interpretations concerning the association of apolipoprotein E (APOE) ε4 with late-onset Alzheimer's Disease in 1993 have overlooked such facts in more than two dozen subsequent Genome-Wide Association Studies (GWAS)-without recognizing that the particular SNP associations could not discriminate APOE alleles. The two APOE allele-defining SNPs (for APOE ε2, APOE ε3, or APOE ε4) were not included on the commercial platforms used before 2012 (Fig. 1) [1, 2] . Most of the AD GWAS literature pre-dates that 2012 and exclude further analyses of the "APOE" region, whereas a few newer studies now use the Illumina OmniQuad Array (Fig. 1 ). The precise nature of this "interpretation problem" might be better understood in the context of the rapidly developing GWAS field between 1997 and 2012. In a 1997 Science Commentary entitled "Snipping Away at Genome Patenting", Dr. David Cox (a distinguished and popular geneticist) was quoted as saying that SNP patents could become "a nightmare" for companies and basic researchers alike, and that Francis Collins, then head of the National Genome Research Institute (NHGRI), and others would like to "head off" [3] . In 1998, the formation of The SNP Consortium provided an opportunity for industry to work with the NIH to insure that SNPs would be in the public domain to promote widespread adoption in research [4] . The SNP Consortium was formed and supported by 10 pharmaceutical companies as a partnership to publish and distribute enough SNP data into the public domain to diminish the likelihood of proprietary SNP panels [4] . GlaxoWellcome (GW) Genetics had organized the Consortium and, as SNPs were identified, preceded to test whether enabling GWAS with new high volume/low cost commercially available genotyping platforms would be feasible.
The association of APOE ε4 with so-called late-onset sporadic Alzheimer's disease had been previously discovered in 1992 and published in 1993, a decade before any commercial GWAS platforms became available [1, 2] . In 1997, the GW Genetics Group created a relatively dense map (at that time) of newly identified human SNPs from a 2-megabase region on either side of the APOE gene locus. This region was used to model a GWAS and test whether a GWAS approach, using the association of APOE and AD, would be easily recognized. This proof of concept was based on a simple question: could future GWAS screening identify the location of the APOE locus associated with age of onset distributions of AD if there were no prior knowledge [5] [6] [7] .
The APOE locus was confirmed-including SNPs from APOE and SNPs within PEREC1 (an expressed gene later discovered to be TOMM40) and APOC1. Specific alleledetermining APOE SNPs as well as SNPs from the other recognized genes and noncoding SNPs in the linkage disequilibrium (LD) region provided very strong statistical evidence of association. Eventually, the Human Genome Project clearly defined this region as having strong LD.
GW had also collected well-phenotyped clinical cohorts with banked deoxyribonucleic acid (DNA) for 17 different diseases. After a merger created GlaxoSmithKline [GSK] in 2000, newly available commercial SNP platforms were purchased from several technology companies to perform parallel beta pilot testing. SNP genotyping platforms were directly compared using the same DNA samples to determine functional characteristics of each platform. By 2006, GSK had completed GWAS studies from seven different disease cohorts, using several different platforms. The results clearly demonstrated that SNPs from immediate neighbors within the "APOE" locus had a unique association with AD. A similarly robust association was not observed at any measured locus in the other six diseases. It was clear that this strategy would not be generalized. These negative GWAS studies were not increased in size to detect small signals and were concluded in 2007. Two of the commercial platforms (without the two APOE allele-determining SNPs) became widely used as the winning platforms. GWAS became the hot area of research throughout medicine fueled by commercial SNP panels. The results from the "APOE" region were (and still are) unique. Instead of simply adding more patients in more diseases, at an extraordinary cost, GSK genetics initiated a post-GWAS strategy using phylogenetic mapping to dissect the "APOE" linkage disequilibrium (LD) region.
GWAS has provided massive information to the public databases: yet, it should be considered whether the data are representative of a gene or actually an LD region. Identification of a "gene" located near a particular SNP on the platform gets reported frequently from GWAS from many diseases, including associated press releases. Historically, microsatellite markers for genetic mapping had been anchored to genes. However, with the success of the Human Genome Project, genetic markers can be accurately mapped to primary DNA. Currently, GWAS is transitioning to next-generation sequencing (NGS), but it has unfortunately become second nature to refer to specific SNPs with low odds ratio association data as "disease genes," even if the SNP is at some distance from the nominated gene. As will be discussed below, even common complete NGS technologies in 2016 do not accurately measure the length of short tandem repeat (STR) sequences, which may indeed be more important to define common complex diseases from more than a million variable structural variations in the human genome. Recently, there has been some progress in measuring repeat length sequences accurately, but expectations have been high for this technology for the past several years. One of the experimental data sets being investigated is the TOMM40 0 523 locus. When Dr. David Botstein joined the Board of Pac-Bio in 2012, he stated in the press release [8] "We are moving toward an exciting era where the cost of producing sequencing information is going down, and now the emergence of the high-quality, multi-kilobase sequence will be a double game changer. Even with today's advanced sequencers, a lot of good biology is being left on the table because we cannot fully assemble genomes for the many organisms for which there is no reference, or because we are missing difficult to sequence regions of critical variation. Pacific Biosciences' longread technology offers the field something that currently does not otherwise exist-the ability to create high quality de novo assemblies, improve re-assemblies for complex organisms, and understand DNA modifications within sequences."
TOMM40 and AD
In 2005, GSK was unable to fully sequence the "APOE" LD region for phylogenetic mapping purposes. A variable length of region in intron 6 of the TOMM40 gene could neither be sequenced in two GSK sequencing laboratories nor in 5 of 6 commercial sequencing companies. However, one out-sourced laboratory accomplished the sequencing successfully (Polymorphic Technologies, Inc.; Alameda, CA). Using their specialized methods (now validated), all the SNPs and multiple repeat sequences in the LD region were sequenced. Sanger sequencing protocols were validated to map the DNA strands and to begin defining variable nucleotide length repeats on the same chromosomal strand (cis). GSK used phylogenetic mapping to place evolutionary variants within the TOMM40-APOE-APOC1 LD region in welldefined clades. Fig. 2A depicts the phylogenetic map, as published, for an Arizona Alzheimer's Disease Research Center (ADRC) AD cohort [9] . Similar lengths of polyT repeats at the TOMM40 0 523 locus were characteristic of several major phylogenetic clades in another independent Caucasian cohort (Canadian). The clusters of polyT length polymorphisms were subsequently associated with the age of onset distributions, using a prospectively ascertained clinical AD cohort followed at the Bryan ADRC. Fig. 2B illustrates the phylogenetic clade intersection which separates the ancestral Long TOMM40 0 523 alleles from the separate VL and S clades [9] [10] [11] .
The frequency of major clusters of polyT length in major clades differs in multiple ethnic groups [10, 11] . The accuracy of the polyT lengths using validated methods (Polymorphic DNA Inc. for research use, and Quest Diagnostics in more than 22,000 clinical trial tests under Food and Drug Administration standards) allowed the observation in African-Americans of new cis-haplotypes that had not been observed in multiple Caucasian populations studied at more than 50 centers in the United States, United Kingdom, Germany, Switzerland, Australia, and Russia (Siberia) participating in the TOMMORROW clinical trial testing an age-dependent risk algorithm using TOMM40 0 523, APOE, and age of onset [12, 13] . Within Caucasian cohorts from around the world, the pattern of phylogenetic maps was shown to be highly reproducible [9, 13] . More than 28 different polyT lengths were mapped to several large evolutionary clades. The large clades were grouped into three polyT length clusters which were labeled short (S 5 ,20 T's), long (L 5 20-30), and very long (VL 5 30) polyT lengths. Studies of several Caucasian cohorts demonstrated that: S lengths are in phase cis to APOE ε3 and APOE ε2 alleles; the L alleles segregate cis to APOE ε4 chromosomes. Nearby SNPs that are also mapped within each of these large clades also may reflect association to age of onset distributions. The TOMM40 0 523 polyT lengths connected to APOE alleles could now allow TOMM40 0 523-APOE cis-haplotypes to define age of onset distributions for .97% of Caucasians, connecting the clinical phenotype of AD to APOE genotypes, as was reported in 1993 [2, 12] . The major distinction of this work is not simply the association of the region with AD but the informative estimates of risk for .97% of individuals. It is important to note that there are three additional distributions of APOE ε3/3 carriers (S-S, S-VL, and VL-VL) that are now providing differential age of onset information using TOMM40 0 523 that were not available using APOE ε4 alone (4/4, 3/4, and 2/4). Both APOE ε2/2 (1%-2%) and APOE ε2/4 (1%-2%) are uncommon genotypes in Caucasian AD patients, so there are not yet enough age of onset data points to provide a distribution in clinical cohorts, but such data will be available and shared publically when the TOMMORROW clinical delay of mild cognitive impairment onset trial is completed [12] . The TOMM40 0 523/APOE cis-haplotypes are even more informative, including data from several ongoing studies of other ethnicities, including AfricanAmericans, that recognize cis-haplotypes rarely encountered in Caucasians [10] [11] [12] 15 ].
Precision versus accuracy
Between 1993 and 1995, most AD geneticists were skeptical of the role of APOE ε4 in sporadic AD [14] . However, as APOE isotyping (using gel electrophoreses to distinguish the apoE proteins) was available within several hospitals (primarily European), the APOE ε4 association with AD was confirmed rapidly [15] . The association has held up remarkably as a confirmed risk factor over the years [15] [16] [17] [18] . However, it was recommended in 1997 by an NIH Conference Panel that APOE ε4 should not be used as a diagnostic in clinical practice [19] . Because Duke University owned the issued patent on the association of APOE ε4 and AD, Duke made the decision to exclude the two SNPs that determine the APOE alleles from the developing GWAS platforms so that the two SNPs would not be used inappropriately as a clinical genetic test for a disease with inadequate therapy but would be available for use in research and as a clinical pharmacogenetic test [20] . This did discourage the use APOE genotyping as a commercial medical diagnostic product. However, when the early SNP platforms were being beta-tested, and until 2012, commercial GWAS platforms used for AD studies contained neither coding SNPs nor any SNPs from introns of APOE (Fig. 1) . The use of other SNPs in the so-called "APOE" LD region allowed precise location to the LD area but were not accurate for expanding to APOE genetics [20] . Four of the 5 SNPs on the most used platforms before 2012 used noncoding SNPs outside the APOE locus to impute the LD region and could not make an accurate call of specific APOE alleles, as measured by the two SNPs that define the gene variance.
The first wave of GWAS studies in AD, before 2012, represents other alleles that may be linked to APOE but are not direct assessments of APOE ε4 alleles [20, 21] . The "APOE region" is the common slang for relating association data that actually represent the LD region and not APOE alleles for any individual. When genetic rigor is applied, the data represent TOMM40 SNPs more accurately than APOE. Statements made in 2012 about separating an "APOE" effect from a TOMM40 effect are not possible, because neither the TOMM40 0 523 alleles or the APOE alleles were specifically studied [22] . The GWAS data are fine for association within the LD region but do not test or recognize specific cis-haplotypes available from phylogenetic maps. A clinically important difference is that TOMM40 0 523 genotyping is more informative in .97% of the Caucasian population, then only 29% of APOE ε4 carriers and, for the first time, APOE ε3/3 patients can be divided with two specific APOE ε3-TOMM40 0 523 cis-haplotypes into three groups (S/S, S/VL, and VL/VL) with distinct age of onset curves [9, 12] .
This does not mean that apoE isoforms are neither involved in the pathogenesis of AD nor does it mean that TOMM40 is the gene. It does suggest relevance of two adjacent genes to the rate of clinical expression of AD. The evidence for a known functional interactions within human metabolism is emerging, beginning with the differential effects of APOE isoforms on mitochondrial dynamics, differential effects on mitochondrial metabolism mitochondria, and decreased mitochondrial dynamic functions [23] . Using later SNP platforms with APOE allele-specific SNPs is still less robust than phased phylogenetic mapping. The genetic association of TOMM40 0 523/APOE cis-haplotypes is far more accurate to translate to individuals in the population than measuring a few SNPs from TOMM40 and calling it "APOE" data. For the first time, three different ages of onset distribution can now be attributed to the largest group of AD patients, APOE ε3/3 (60% of Caucasians), by delineating three TOMM40 0 523 sub-classes (S-S, S-VL, and VL-VL), raising the informative data to .97% of individuals, compared to 29% with APOE4 alone [12] . TOMM40 0 523 association with AD age of onset has received the same skeptical welcome that had been the case for APOE in the early 1990s [3, 16] . In one early "Online First" Editorial published in August 2012 it was stated: "Not only did genetic variants within APOE show association with AD but single-nucleotide polymorphisms (SNPs) around the locus also presented strong associations with the disease" [22] . The operative word is "also," because the two dozen GWAS studies that had been reported by that time did not measure the two SNPs that define APOE alleles. The authors also stated that "it is very difficult to attribute a genetic and APOEindependent role of TOMM40." This is especially true when APOE alleles and TOMM40 0 523 are not specifically measured. Because the TOMM40 0 523 region can now be phased on the same DNA strand, the cis-haplotypes data can be far more accurate and informative than genotypes or SNP haplotypes. Even newer SNP platforms that contain the two specific APOE SNP alleles cannot provide phased chromosomal relationships.
AD GWAS articles had discussed only the "APOE" region, ignoring the TOMM40 0 523 data although four of the five SNPs studied were located within TOMM40. Clearly, much of the field did not realize what they were actually measuring. To make life easier in finding new genes, most GWAS studies excluded the entire "APOE" LD region in their analyses. [21] However, the AD GWAS published by our group at GSK discussed the possibility of another gene, later defined as TOMM40 but present in our 1998 article as PEREC-1, before it was known that this was the locus for the translocase of the external mitochondrial membrane channel [5, 20] .
It is inaccurate to attribute all late-onset AD genetics to APOE (or TOMM40). However, it must be realized that it is also inaccurate to depend solely on small statistical effects to nominate a gene. GWAS uses a common correction for a million SNP tests to generate statistical associations. A designated gene that is near to a specific SNP or several SNPs may be precise localization, perhaps even within LD. Accuracy and precision are not one in the same. Although the precise molecular pathogenesis affecting mitochondria leading the increased risk of AD remains undetermined, the "precision" of localization to the "APOE LD region" has diverted consideration of fine mapping of the actual variants within the LD region over the past 5 years. TOMM40 0 523 is a structural variation locus that is coded at a precise genetic locus with more than two dozen length variations. There is sufficient variation to be associated with individual age of onset distributions-not just association to large groups of patients labeled as AD without taking into account the w10% error in AD diagnosis in living patients. The important point is that APOE became "the" referenced gene rather than simply an important gene in a broader view of the LD field. This has diverted consideration of the LD genetic findings and hampered efforts to develop new therapeutic options to ease the burden of AD. Being precise in locating the "field," but inaccurate and off-target is of little benefit.
Considerations and speculations
As a broader view important to GWAS interpretations in other diseases, imputation of a nearby SNP from GWAS and assigning a "gene name" to it needs to be carefully noted [21, [24] [25] [26] . Naming such genes misses the point that other SNPs and structural variants, like the polyT variants of TOMM40 0 523, can provide a clearer view of the nearby field and other more precise data can be observed within the field [9, 12, [26] [27] [28] . Perhaps, the most important observations with respect to TOMM40 and the association of age of onset of AD is that there are variable length polyT repeats at a single locus within intron 6 of TOMM40 which carry the critical phenotype of age of onset. The distribution of this single nucleotide repeat is directly related to the AD phenotype. The pathophysiology field for AD is broader than simply amyloid or tau deposition. APOE ε4 is commonly imputed as the important gene and is certainly clearly involved as a significant biological contributor. Similarly, the TOMM40 0 523 variants may be involved with alternative splicing or mRNA expression [27, 30] .
The future may have new preventative and treatment drugs with different efficacy pharmacogenetic profiles, dependent on the cis-haplotypes of TOMM40 0 523 and APOE [12] . TOMM40 is the main channel through which proteins and peptides must traverse to support the dynamic functions of mitochondria, identifying pathogenic factors than may result through changes in mRNA expression and/or alternative splicing may be critical in the future [27] [28] [29] [30] . We know that many aggregating proteins bind and traverse through Tom40 protein channel and aggregate within the channel. Besides apoE4 and apoE3, there are more than 30 proteins associated pathologically with brain plaques in AD. APP and amyloid may exert catalyzing effects on the rate of disease expression based on heterogeneous interactions with the mitochondrial channel through which it is meant to travel [30] . Studying the amyloid protein as a component of the pathogenesis is critical, but we need to know the right drug target for drug discovery [31] . None of the previously mentioned GWAS studies ever demonstrated statistical association attributed to the APP gene [31] [32] [33] [34] .
Tom40 dysfunction has been noted in Parkinson's disease and may also relate to Huntington's disease [33, 34] . Unfortunately, there are many degenerative neurological diseases in which Tom40 remains unstudied. Mitochondrial dynamics are affected by apoE4 differently than by apoE3 [35] [36] [37] [38] [39] [40] . The evidence for mitochondrial effects in the brain, particularly in glucose and oxygen utilization, is quite clear and evident from many positron imaging experiments [41] . Oxygen and glucose are primarily processed by mitochondria, especially in the brain. ApoE isoforms and Tom40 variants may affect that metabolism probably from birth. The course of AD may be accelerated by the inheritance of APOE ε4, with plaques and tangles representing visible damage. Finally, TOMM40 0 523 is related to AD pathogenesis based on the .97% informative age of onset distributions. ApoE, amyloid, and synuclein proteins are interactive with Tom40 [33, 42] . The Tom40 protein forms the channel by specific protein interactions involving several intrinsic proteins and multiple signaling proteins [43, 44] . Basic science studies focusing on the structure and function of TOMM40 and its associated interactions are now entering the scientific literature [45] [46] [47] [48] and will accelerate drug discovery and development from determining the role of mitochondria and relevant mechanisms of pathogenesis.
RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the Alzheimer's Disease GWAS literature using traditional (e.g., PubMed) sources, as well as press releases with respect to the interpretation of limited genetic data. The content of commercial GWAS singlenucleotide polymorphism (SNP) platforms and the designation of small odds ratios as evidence for declaring a new "AD gene" of small effect was the primary focus.
2. Interpretation: Our findings highlighted the limitations of the GWAS platforms compared to phylogenetic mapping of sequenced data. The data utilized for genetic identity were contrasted to phylogenetic mapping of the APOE and TOMM40 linkage disequilibrium region. This LD region has been acknowledged as robust, but is usually formally excluded from additional genetic analyses in order to focus on new "genes."
3. Future directions: This Perspective proposes a genetic framework for the confirmation of "new gene" hypotheses using sequencing of proposed LD regions and highlighting the role of highly polymorphic short tandem repeat sequences related to structural variants located throughout the genome.
